The EVERBIO II ( Comparison of Everolimus - and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents II ) trial was a single-center , assessor-blinded study of 240 patients randomly assigned in a 1:1:1 ratio to EES , BES , or BVS .